1200 Pharma
Culver City, US · 2 known investors
Develops novel oncology therapeutics using breakthrough medicinal chemistry technology and biomarker-driven assays to accelerate drug discovery and clinical approval timelines.
Founders & leadership
BS
Brian StoltzDirector
MA
Mark AttanasioDirector
DC
David ChangDirector
DL
David LicataDirector
DS
Dennis SlamonDirector
Investors · 2
Reported raises · per SEC filings
Form D private placements▶$2.3MraisedApr 2024 · 30 investors · Other TechnologyRule 506(b)
▶$2.3MraisedApr 2024 · 30 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Brian StoltzDirector
- Mark AttanasioDirector
- David ChangDirector
- David LicataDirector
- Dennis SlamonDirector
- Amount sold
- $2.3M
- First sale
- Apr 2024
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedDec 2019 · 5 investors · Other TechnologyRule 506(b)
▶$5.5MraisedDec 2019 · 5 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- DAVID LICATAExecutive Officer
- LEE SAILORExecutive Officer
- Offering amount
- $5.5M
- Amount sold
- $5.5M
- Minimum investment
- $10K
- First sale
- Nov 2019
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
▶$6.2MraisedNov 2017 · 2 investors · Other TechnologyRule 506(b)
▶$6.2MraisedNov 2017 · 2 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Lee SailorExecutive Officer
- David LicataExecutive Officer
- Offering amount
- $12.5M
- Amount sold
- $6.2M
- Minimum investment
- $10K
- First sale
- Nov 2017
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.